New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
06:34 EDTALXNAlexion sees FY13 non-GAAP EPS $2.82-$2.92, consensus $2.81
Sees FY13 $1.49B-$1.51B, consensus $1.49B. R&D expenses are expected to be in the range of $285M-$295M, and SG&A expenses in the range of $425M-$435M. The non-GAAP effective tax rate, reported on a cash tax liability basis, is expected to be in the range of 7%-9%.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
06:31 EDTALXNAlexion announces $500M share repurchase program
Alexion Pharmaceuticals announced that the company’s board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the company’s current program, which has approximately $22M remaining of its previously authorized $400M.
December 12, 2014
08:01 EDTALXNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 10, 2014
16:20 EDTALXNAlexion reports Soliris granted orphan drug designation in Japan
Subscribe for More Information
December 9, 2014
05:33 EDTALXNAlexion presents Soliris data at ASH
Subscribe for More Information
December 7, 2014
14:10 EDTALXNAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use